In the present work, we sought to validate the use of VEGF-A, sFlt-1, Ang-1 and Ang-2 levels as biomarkers of septic shock development in a larger and independent cohort of patients with cancer-associated FN, in a more clinically relevant scenario regarding the use of a sepsis biomarker. The gene discussed is ANGPT2; the disease is Sepsis.